Skip to main content
Vai all'homepage della Commissione europea (si apre in una nuova finestra)
italiano it
CORDIS - Risultati della ricerca dell’UE
CORDIS
Contenuto archiviato il 2024-04-30

Molecular mechanisms of angiogenesis associated to cancer progression : targets for new diagnostic tools and for new anticancer therapeutic approaches

Obiettivo



Angiogenesis is crucial in the progression of solid tumours and in the formation of metastases.
Although tumours 1-2 mm diameter can receive nutrients by diffusion, further growth depends on the formation of a network of new vessels. Furthermore these new vessels are target for invading tumour cells and represent the best way to spreading in other organs. Many clinical studies support this model and have concluded that the number and the density of vessels in different human cancers directly correlate with their potential to progress and produce metastases. In animal models, angiogenesis inhibitors gave favourable results on cancer progression. However, there are some conflicting data, such as the observation that not all angiogenic tumours produce metastases, or that metastases develop many years after the appearance of a well-vascularised tumour.

These observations indicate that a change in the phenotype of endothelial cells in the tumour is essential for the progression of the disease, rather than a simple increase of number of vessels.

The general objective of this proposal is to develop new instruments (diagnostic, therapeutic, experimental) on tumour angiogenesis to improve the information required for the prognosis and search new therapeutic strategies for the treatment of cancer. These tools (mAbs to vascular cells, to angiogenic factors and their receptors, cDNAs, animal models, antagonist molecules) will be developed from the molecular and biological knowledge's obtained by the different partners. The availability of more sophisticated instruments and their evaluation in animal models and in selected series of patients will provide an invaluable asset to public health and European industry interested in the development of diagnostic and therapeutic agents for cancer disease. Therefore the identification of an endothelial phenotype more favourable to cancer progression, the development of Abs to this phenotype, or to molecules involved in it their expression (Section 1 and 2) will be a central focus of this project.

Section 2 will study molecules which regulate angiogenesis and their mechanisms of action. The aim of this section is to produce specific mutants with antagonistic activity or molecules which interfere with signal transduction pathways.

Section 3 will develop new animal models to test the reagents prepared by sections 1 and 2 and to define different angiogenic profiles. The diagnostic and therapeutic usefulness of tools developed by section 1 and 2 will be tested in clinical trials (Section 4).

The implementation of this project is expected to have a broad impact on the diagnostic and therapeutic strategies concerning solid tumours and to favour a better management of this disease.

Campo scientifico (EuroSciVoc)

CORDIS classifica i progetti con EuroSciVoc, una tassonomia multilingue dei campi scientifici, attraverso un processo semi-automatico basato su tecniche NLP. Cfr.: Il Vocabolario Scientifico Europeo.

È necessario effettuare l’accesso o registrarsi per utilizzare questa funzione

Programma(i)

Programmi di finanziamento pluriennali che definiscono le priorità dell’UE in materia di ricerca e innovazione.

Argomento(i)

Gli inviti a presentare proposte sono suddivisi per argomenti. Un argomento definisce un’area o un tema specifico per il quale i candidati possono presentare proposte. La descrizione di un argomento comprende il suo ambito specifico e l’impatto previsto del progetto finanziato.

Invito a presentare proposte

Procedura per invitare i candidati a presentare proposte di progetti, con l’obiettivo di ricevere finanziamenti dall’UE.

Dati non disponibili

Meccanismo di finanziamento

Meccanismo di finanziamento (o «Tipo di azione») all’interno di un programma con caratteristiche comuni. Specifica: l’ambito di ciò che viene finanziato; il tasso di rimborso; i criteri di valutazione specifici per qualificarsi per il finanziamento; l’uso di forme semplificate di costi come gli importi forfettari.

CSC - Cost-sharing contracts

Coordinatore

Università degli Studi di Torino
Contributo UE
Nessun dato
Indirizzo
Via Santena 5/BIS
10126 Torino
Italia

Mostra sulla mappa

Costo totale

I costi totali sostenuti dall’organizzazione per partecipare al progetto, compresi i costi diretti e indiretti. Questo importo è un sottoinsieme del bilancio complessivo del progetto.

Nessun dato

Partecipanti (8)

Il mio fascicolo 0 0